Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)
Phase 4
Completed
- Conditions
- COVID-19 PneumoniaCough
- Interventions
- Drug: LianHuaQingWen GranulesDrug: Kesuting syrup
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT05366231
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
Phase 2
Active, not recruiting
- Conditions
- Type2 DiabetesDiabetic Retinopathy
- Interventions
- Drug: Tangningtongluo tablets
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT05007262
- Locations
- 🇨🇳
Gansu Provincial Hospital of traditional Chinese Medicine, Lanzhou, Gansu, China
🇨🇳Chongqing hospital of traditional Chinese Medicine, Chongqing, Chongqing, China
🇨🇳People's Hospital of Anshun City Guizhou Province, Anshun, Guizhou, China
Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis
Phase 4
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Guli capsuleDrug: Kangguzengsheng capsule
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT02484508
- Locations
- 🇨🇳
Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing, Beijing, China
The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis
Phase 2
Completed
- Conditions
- General Disorders and Administration Site Conditions
- Interventions
- Drug: Tangning Tongluo Capsule
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT02174042
- Locations
- 🇨🇳
Nanmeng Tianyuan hospital; Dongfang Hospital; China-Japanese Friendship Hospital, Beijing Shi, Guizhou, China
Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule
Phase 1
Completed
- Conditions
- Accidental Exposure While Preparing Drug for Administration
- Interventions
- Drug: TNTL capsuleDrug: Placebo
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT02161276
- Locations
- 🇨🇳
Tianyuan Hospital of Guiyang City, Guiyang, Guizhou, China
© Copyright 2025. All Rights Reserved by MedPath